Attached files
| file | filename |
|---|---|
| EX-10.17 - Cingulate Inc. | ex10-17.htm |
| EX-10.16 - Cingulate Inc. | ex10-16.htm |
| EX-10.15 - Cingulate Inc. | ex10-15.htm |
| EX-10.14 - Cingulate Inc. | ex10-14.htm |
| EX-10.13 - Cingulate Inc. | ex10-13.htm |
| EX-10.12 - Cingulate Inc. | ex10-12.htm |
| EX-10.11 - Cingulate Inc. | ex10-11.htm |
| EX-10.10 - Cingulate Inc. | ex10-10.htm |
| EX-10.9 - Cingulate Inc. | ex10-9.htm |
| EX-10.8 - Cingulate Inc. | ex10-8.htm |
| EX-10.7 - Cingulate Inc. | ex10-7.htm |
| EX-10.6 - Cingulate Inc. | ex10-6.htm |
| EX-10.5 - Cingulate Inc. | ex10-5.htm |
| EX-10.4 - Cingulate Inc. | ex10-4.htm |
| EX-10.3 - Cingulate Inc. | ex10-3.htm |
| EX-10.2 - Cingulate Inc. | ex10-2.htm |
| EX-4.1 - Cingulate Inc. | ex4-1.htm |
| EX-3.2 - Cingulate Inc. | ex3-2.htm |
| EX-3.1 - Cingulate Inc. | ex3-1.htm |
| EX-2.1 - Cingulate Inc. | ex2-1.htm |
| S-1 - Cingulate Inc. | forms1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Managers
Cingulate Therapeutics LLC
We consent to the use of our report dated May 21, 2021, with respect to the consolidated financial statements of Cingulate Therapeutics LLC and subsidiaries, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
| /s/ KPMG LLP |
| Kansas City, Missouri |
| September 9, 2021 |